Cardiovascular Disease: Modern Risk Assessment
How polygenic risk scores, wearable biomarkers, and AI-driven ECG analysis are transforming early detection and personalized prevention strategies.
Comprehensive, expert-verified articles spanning clinical practice, pharmacology, medical history, emerging therapies, and global health. Updated continuously by licensed professionals and peer-reviewed researchers.
From early vaccine development to targeted cancer treatments and genetic disorder interventions, mRNA technology is reshaping modern therapeutics. This comprehensive review traces the science, regulatory pathways, and ethical considerations driving the next decade of medicine.
How polygenic risk scores, wearable biomarkers, and AI-driven ECG analysis are transforming early detection and personalized prevention strategies.
Understanding how the brain rewires itself post-injury, and the clinical protocols leveraging constraint-induced movement therapy and neuromodulation.
A clinical overview of PD-1/PD-L1 and CTLA-4 targeting therapies, resistance mechanisms, and combination strategies in advanced carcinomas.
Exploring non-dopaminergic mechanisms, reduced metabolic side effects, and the clinical shift toward multimodal psychiatric treatment plans.
Lessons from WHO coordinated responses, surveillance system architectures, and the role of genomic sequencing in real-time outbreak tracking.
The evolution of computer-assisted surgery, haptic feedback integration, and outcomes in minimally invasive urological and cardiothoracic procedures.
Indications, leadless technology advancements, and long-term survival benefits in primary vs. secondary prevention cohorts.
From amyloid-beta plaques to tau tangles: how PET imaging, CSF assays, and antisense oligonucleotides are shifting treatment paradigms.
Bridging geographic disparities through asynchronous care, mobile health units, and AI triage systems in low-resource settings.